144 related articles for article (PubMed ID: 38286976)
1. Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma.
Dasgupta P; Rousseau JF
J Neurooncol; 2024 Feb; 166(3):569-574. PubMed ID: 38286976
[TBL] [Abstract][Full Text] [Related]
2. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
Jo J; Donahue J; Sarai G; Petroni G; Schiff D
Neuro Oncol; 2022 Mar; 24(3):455-464. PubMed ID: 34383073
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
4. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
6. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
7. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
10. Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients.
Jin MC; Sussman ES; Feng AY; Han SS; Skirboll SL; Berube C; Ratliff JK
Thromb Res; 2021 Aug; 204():126-133. PubMed ID: 34198049
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
15. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Mantia C; Uhlmann EJ; Puligandla M; Weber GM; Neuberg D; Zwicker JI
Blood; 2017 Jun; 129(25):3379-3385. PubMed ID: 28468796
[TBL] [Abstract][Full Text] [Related]
16. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
17. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Martinelli I; Lensing AW; Middeldorp S; Levi M; Beyer-Westendorf J; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Trajanovic M; Gebel M; Lam P; Wells PS; Prins MH
Blood; 2016 Mar; 127(11):1417-25. PubMed ID: 26696010
[TBL] [Abstract][Full Text] [Related]
18. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study.
Glise Sandblad K; Schulman S; Rosengren A; Sörbo J; Philipson J; Hansson PO
J Intern Med; 2023 Dec; 294(6):743-760. PubMed ID: 37641391
[TBL] [Abstract][Full Text] [Related]
19. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
20. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Houghton DE; Vlazny DT; Casanegra AI; Brunton N; Froehling DA; Meverden RA; Hodge DO; Peterson LG; McBane RD; Wysokinski WE
Mayo Clin Proc; 2021 Nov; 96(11):2793-2805. PubMed ID: 34425962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
